MucinB5 Gene Polymorphism and Leucocytes Telomere Length in Interstitial Lung Diseases
NCT ID: NCT06498141
Last Updated: 2024-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-10-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer
NCT05542940
Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
NCT02269878
Different Genetic Features Associated With Hepatic Carcinogenesis
NCT01247506
"Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
NCT06759714
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
NCT02790944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diseased
patients with interstitial lung diseases fulfilling the inclusion criteria.
No interventions assigned to this group
Control
Healthy subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients with active cancer
* End stage renal failure (GFR \< 30 ml/min) or on dialysis
* Liver cell failure
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amera Morad Foad
Assistant Professor of Medical Biochemistry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag university hosoital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-23-02-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.